Analytical Data
-
Gene name
TSLP
- Application
-
Alternative Names
TSLP；Thymic stromal lymphopoietin
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q969D9
-
Expression Region
29-159aa
-
AA Sequence
M+ YDFTNCDFE KIKAAYLSTI SKDLITYMSG TKSTEFNNTV SCSNRPHCLT EIQSLTFNPT AGCASLAKEM FAMKTKAALA IWCPGYSETQ INATQAMKKR RKRKVTTNKC LEQVSQLQGL WRRFNRPLLK QQ
-
Molecular Weight
15 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Thymic stromal lymphopoietin (TSLP) is a cytokine primarily produced by epithelial cells that plays a crucial role in immune regulation and allergy-related responses. It is integral in the differentiation and activation of T helper 2 (Th2) cells, which are associated with allergic disorders such as asthma, atopic dermatitis, and other hypersensitivity reactions. Research has shown that TSLP is not only involved in the initiation of allergic inflammation but also in the maintenance of chronic inflammatory conditions. Given its pivotal role in promoting Th2-driven immunity, TSLP has become a target of interest for therapeutic intervention in treating allergic diseases. The recombinant protein form of TSLP has been developed and studied for its potential to understand its signaling pathways and physiological effects. Through various in vitro and in vivo studies, researchers aim to elucidate the mechanisms by which TSLP influences immune responses and explore its role as a biomarker for allergic diseases, as well as its potential as a therapeutic agent. These investigations seek to pave the way for novel treatments that could mitigate the burden of allergy-related disorders by modulating TSLP activity. As the understanding of the TSLP signaling cascade expands, it offers promising avenues for developing targeted therapies and has garnered significant attention in immunological research aimed at controlling excessive allergic reactions and regulating immune responses more effectively.
